Can a simple blood test predict arthritis drug success?

NCT ID NCT06933134

Recruiting now Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a mathematical model using blood markers can predict how well rheumatoid arthritis patients will respond to a lower dose of the drug rituximab. Thirty adults with RA who already do well on standard-dose rituximab will switch to a lower dose. Researchers will compare the model's predictions to actual disease activity scores to see if it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rituximab (low-dose, 1000 mg once per cycle)
What this could lead to: If successful, this could help doctors predict which rheumatoid arthritis patients will respond well to a lower dose of rituximab, reducing side effects and costs.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to all patients. The biomarker model may not accurately predict responses in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

University hospital
RECRUITING

Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.